By Devika Patel
Knoxville, Tenn., March 27 - Novelos Therapeutics, Inc. said it will raise $5 million in a private placement of shares and warrants.
The company will sell 100 series D convertible preferred shares at $50,000 apiece to a group of institutional investors. The shares pay 9% dividends and are convertible into common shares at $0.65 per share.
Investors also will receive five-year warrants for 3,846,151 common shares, exercisable at $0.65 per share.
The institutional investors are Xmark Opportunity Funds, OrbiMed Advisors, Knoll Capital and Hunt BioVentures.
Rodman & Renshaw, LLC, the agent, will be paid a cash fee.
Located in Newton, Mass., Novelos develops treatments for cancer and hepatitis.
| Issuer: | Novelos Therapeutics, Inc.
|
| Issue: | Series D convertible preferred stock
|
| Amount: | $5 million
|
| Shares: | 100
|
| Price: | $50,000
|
| Dividends: | 9%
|
| Conversion price: | $0.65
|
| Warrants: | For 3,846,151 shares
|
| Warrant expiration: | Five years
|
| Warrant strike price: | $0.65
|
| Agent: | Rodman & Renshaw, LLC
|
| Investors: | Xmark Opportunity Funds, OrbiMed Advisors, Knoll Capital, Hunt BioVentures
|
| Pricing date: | March 27
|
| Stock symbol: | OTCBB: NVLT
|
| Stock price: | $0.53 at close March 26
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
